Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: A case study for statistical issues in efficacy trials

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 969-975

  Gilbert, Peter B ^a,b   Berger, James O ^d   Stablein, Donald ^e   Becker, Stephen ^c   Essex, Max ^g   Hammer, Scott M ⁱ   Kim, Jerome H ^f   DeGruttola, Victor G ^h  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d Duke University   (United States)

^e EMMES CORPORATION   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g Harvard AIDS Institute   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ANTIVIRAL THERAPY; BAYES THEOREM; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NULL HYPOTHESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THAILAND;

AIDS VACCINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; THAILAND; TREATMENT OUTCOME;

EID: 79953019952     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq152     Document Type: Review

References (29)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
2. Burton D.R., Desrosiers R.C., Doms R.W., et al. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303:316. (Pubitemid 38095757)
3. McNeil J.G., Johnston M.I., Birx D.L., Tramont E.C. HIV vaccine trial justified. Science 2004; 303:961. (Pubitemid 38209686)
4. Cohen J. Massive AIDS vaccine study a "modest" success. Sci Insider. 24 September 2009.
5. Cohen J. Unrevealed analysis weakens claim of AIDS vaccine "success." Sci Insider. 5 October 2009.
6. Yang Y., Gilbert P., Longini I.M. Jr., Halloran M.E. A bayesian framework for estimating vaccine efficacy per infectious contact. Ann Appl Stat 2008; 2:1409-31.
7. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. the rgp120 HIV Vaccine Study Group. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
8. Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71.
9. Moore J.P., Ho D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 1995; 9:S117-S136.
10. Rida W., Fast P., Hoff R., Fleming T.R. Intermediate-size trials for the evaluation of HIV vaccine candidate: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195-203.
11. Mehrotra D.V., Li X., Gilbert P.B. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics 2006; 62:893-900.
12. Buchbinder S.P., Mehrotra D.V., Duerr A., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
13. Gray G.E., Bekker L., Churchyard G.J., et al. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study? Retrovirology 2009; 6:P209.
14. Cohen J. Mission improbable: a concise and precise definition of p-value. ScienceNOW Daily News. 30 October 2009.
15. Lachin J.M. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000; 21:167-89. (Pubitemid 30259147)
16. Rosenbaum P.R. The consequences of adjustment for a concomitant variable that has been affected by the treatment. J Roy Stat Soc Ser A 1984; 147:656-66.
17. Robins J.M., Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992; 3:143-55.
18. Frangakis C.E., Rubin D.B.. Principal stratification in causal inference. Biometrics 2002; 58:21-9. (Pubitemid 34194484)
19. Tsiatis A.A., Davidian M., Zhang M., Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med 2008; 27:4658-77.
20. Zhang M., Tsiatis A.A., Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008; 64:707-15.
21. Lu X., Tsiatis A.A.. Improving the efficiency of the log-rank test using auxiliary covariates. Biometrika 2008; 95:679-94.
22. Moore K.L., van der Laan M.J. Covariate adjustment in randomized trials with binary outcomes: targeted maximum likelihood estimation. Stat Med 2009; 28:39-64.
23. Zhang M., Gilbert P. Increasing the efficiency of prevention trials by incorporating baseline covariates. Stat Commun Infect Dis 2010; 2: DOI: 10.2202/1948-4690.1002 Available at: http://www.bepress.com/scid/vol2/iss1/art1. Accessed January 31, 2011.
24. Scharfstein D.O., Rotnitzky A., Robins J.M. Adjusting for nonignorable drop-out using semiparametric nonresponse models. J Am Stat Assoc 1999; 94:1096-146.
25. Shepherd B., Gilbert P., Lumley T. Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. J Am Stat Assoc 2007; 102:573-82.
26. Spiegelhalter D.J., Abrams K.R.,Myles J.P. Bayesian approaches to clinical trials and health-care evaluation. New York: John Wiley & Sons, 2004.
27. Berger J. Could Fisher, Jeffreys and Neyman have agreed on testing (with discussion)? Stat Sci 2003; 18:1-32. (Pubitemid 41461821)
28. Lilford R.J. Ethics of clinical trials from a bayesian and decision analysis perspective: whose equipoise is it anyway? BMJ 2003; 326:980-1.
29. Lee D., Graham B.S., Chiu Y.L., et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004; 190:903-7. (Pubitemid 39120966)